Francis Knuettel II 4/A

What Happened
Francis Knuettel II, Pelthos Therapeutics' Chief Financial Officer (also Treasurer & Secretary), received a grant of 33,472 restricted stock units (RSUs) on July 2, 2025. The grant was reported as an award/acquisition at $0.00 per share (no cash paid). This Form 4 is an amendment to report the grant in Table I; the original grant had been reported previously in Table II.

Key Details

• Transaction date: July 2, 2025. Form 4 filed as an amendment on April 1, 2026. (This amendment indicates the filing was updated after the original filing.)
• Transaction type/code: A = Award/Grant (RSUs). Price reported: $0.00; total reported acquisition value = $0.
• Shares granted: 33,472 RSUs (each RSU represents the right to one share of common stock upon settlement). Amounts adjusted for a 1-for-10 reverse stock split effective July 1, 2025.
• Vesting: One-third vests on July 2, 2026; remaining two-thirds vest in equal quarterly installments over the following two years, subject to continued service.
• Ownership notes: Mr. Knuettel is manager of Camden Capital LLC and co-trustee of the Lara Knuettel Revocable Trust; he may be deemed to beneficially own shares held by those entities but disclaims ownership except to his pecuniary interest.
• Filing note: This is an amended Form 4 (Exhibit 24 — Power of Attorney attached). The amendment was filed several months after the grant date.

Context
RSU grants are compensation awards that vest over time and are typically settled in company stock; they do not require out-of-pocket purchase by the insider. Because this filing reports a grant (not a purchase or sale), it does not, by itself, signal immediate buying or selling interest. The late amendment means the reported detail was updated after the original submission—retail investors should consider timing when using insider filings to assess recent insider activity.